Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.
- Published In:
- Healthcare (Basel, Switzerland), 13(22) (2025)
- Authors:
- Bin Dayel, Faten F
- Database ID:
- RPEP-10163
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10163APA
Bin Dayel, Faten F. (2025). Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.. Healthcare (Basel, Switzerland), 13(22). https://doi.org/10.3390/healthcare13222922
MLA
Bin Dayel, Faten F. "Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.." Healthcare (Basel, 2025. https://doi.org/10.3390/healthcare13222922
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide in Diabetic Kidney Disease: Integrating Clinical..." RPEP-10163. Retrieved from https://rethinkpeptides.com/research/bin-2025-semaglutide-in-diabetic-kidney
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.